Approved indications
• Prevention of febrile neutropenia: In adults with non-myeloid cancers receiving myelosuppressive chemotherapy associated with a clinically significant risk of febrile neutropenia.
• Acute radiation syndrome: To increase survival in adults acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).

Off-label uses
• Clinicians may occasionally use pegfilgrastim products in settings where reducing neutropenia is important but not specifically listed in labeling (for example, certain chemotherapy regimens or timing strategies); such uses rely on extrapolation from pegfilgrastim/filgrastim data and are generally supported by moderate- to high-quality evidence for the class rather than Ziextenzo-specific trials.

Efficacy expectations
• With chemotherapy, neutrophil counts typically begin to recover sooner, and the duration of severe neutropenia is shortened by several days compared with no G-CSF support, lowering the risk of febrile neutropenia and related hospitalizations.
• In acute radiation syndrome, treatment improves blood cell recovery and overall survival compared with supportive care alone, based largely on animal studies and experience with related drugs, as human efficacy trials are not ethical or feasible.
• Ziextenzo is a biosimilar to reference pegfilgrastim, so its clinical efficacy is expected to be highly similar to Neulasta and other pegfilgrastim products when used at comparable doses.

Typical dosing and how it is given
• Chemotherapy-induced neutropenia: For most adults, the usual dose is 6 mg given as a single subcutaneous injection once per chemotherapy cycle, typically at least 24 hours after completion of cytotoxic chemotherapy and not within 14 days before the next chemotherapy cycle.
• Acute radiation syndrome: Dosing is weight-based and given as subcutaneous injections on a schedule defined by specialized protocols; clinicians determine the exact dose and timing based on body weight and radiation exposure scenario.
• Route: Ziextenzo is given subcutaneously (under the skin), usually in the abdomen, thigh, or upper arm, by a healthcare professional or trained patient/caregiver using a prefilled syringe.

Special dosing instructions
• Do not give on the same day as myelosuppressive chemotherapy; timing is important to avoid potential reduction in effectiveness.
• The dose may be delayed, omitted, or adjusted depending on blood counts, treatment goals, and tolerance.
• Follow your oncology team’s instructions closely regarding injection technique, rotation of injection sites, and safe handling of syringes.

Missed dose guidance
• If a scheduled dose is missed, contact the prescribing clinician as soon as possible for instructions; do not give an extra dose without medical advice.
• Because dosing is tied to chemotherapy or radiation timing, the care team may adjust the schedule rather than simply “making up” a dose.

Overdose
• Taking more than the prescribed amount can cause very high white blood cell counts, severe bone pain, and increased risk of serious side effects such as spleen problems or lung complications.
• In case of suspected overdose, seek urgent medical attention or contact poison control; bring the medication package so providers can verify the product and amount.

Common side effects
• Very common: Bone pain, muscle or joint pain, pain in arms/legs, and headache; these often begin within a few days after injection and are usually mild to moderate, sometimes requiring over-the-counter pain relievers if approved by the clinician.
• Other frequent effects: Injection-site redness or discomfort, fatigue, nausea, and mild fever.

Serious or rare adverse effects (seek immediate medical attention)
• Signs of spleen problems such as left upper belly or shoulder-tip pain, feeling of fullness, or sudden severe pain (possible splenomegaly or splenic rupture).
• Sudden trouble breathing, shortness of breath, or rapid weight gain, which can suggest acute respiratory distress syndrome (ARDS), capillary leak syndrome, or serious allergic reaction.
• Severe allergic or anaphylactic reactions: hives, swelling of face or throat, difficulty breathing, chest tightness, or feeling faint.
• Unusual bruising or bleeding, or small red or purple spots on the skin, which may signal rare immune-mediated conditions like thrombocytopenia or glomerulonephritis.

Warnings and precautions
• Use with caution in people with sickle cell disease (risk of sickle cell crisis), history of severe lung disease, or prior serious reactions to pegfilgrastim, filgrastim, or other G-CSFs.
• Kidney or liver impairment generally does not require routine dose adjustment, but monitoring is individualized based on overall health and concurrent treatments.
• Pregnancy and breastfeeding: Human data are limited; use only if the potential benefit justifies potential risk, and discuss timing around chemotherapy, pregnancy planning, and breastfeeding with the oncology team.
• Not established for routine use in children; Ziextenzo is primarily used in adults in the United States.

Safety compared with similar drugs
• The overall safety profile is similar to reference pegfilgrastim and other G-CSF agents; biosimilar approval requires no clinically meaningful differences in safety, purity, or potency compared with the reference product.

Side-effect reporting and safety updates
• Patients and caregivers can report suspected side effects to the FDA MedWatch program or to the manufacturer, and clinicians monitor evolving safety information through updated prescribing information and regulatory safety communications.

Drug and other interactions
• Myelosuppressive chemotherapy: Ziextenzo should not be administered within 24 hours before or until at least 24 hours after cytotoxic chemotherapy, as concurrent use can reduce its effectiveness on white blood cell recovery.
• Radiation: In the acute radiation setting, it is part of coordinated management; doses must be timed according to established protocols.
• Other medicines and supplements: No major direct drug–drug interactions are common, but tell your care team about all prescription and over-the-counter drugs, vitamins, and herbal products, especially those that affect the bone marrow, immune system, kidneys, or lungs.
• Alcohol and food: No specific food or alcohol interactions are known; however, overall health, hydration, and liver function can influence tolerance to chemotherapy and supportive medications.

Precautions and conditions requiring extra care
• History of hypersensitivity to pegfilgrastim, filgrastim, or E. coli–derived proteins is a contraindication.
• Sickle cell disease, preexisting splenomegaly, or certain lung conditions (e.g., interstitial lung disease) require close monitoring due to higher risk of serious complications.
• Patients with autoimmune disease, kidney problems, or receiving other marrow-stimulating agents may need individualized monitoring and dose planning.

Monitoring needs
• Regular complete blood counts (CBC) are used to monitor white blood cells and other blood components, especially during chemotherapy cycles.
• Clinicians may monitor for signs of splenic enlargement, lung complications, capillary leak syndrome, and kidney involvement based on symptoms, exam findings, and, when indicated, imaging or laboratory tests.

Q: What is Ziextenzo used for?
A: Ziextenzo helps reduce the risk of infection in adults receiving certain chemotherapy that lowers white blood cells and is also used to improve survival in adults exposed to high levels of radiation that damage the bone marrow.

Q: How long does it take for Ziextenzo to start working?
A: Ziextenzo begins stimulating white blood cell production within hours, but blood count improvements are usually seen over several days, helping shorten the period of very low counts after chemotherapy or radiation.

Q: Can I inject Ziextenzo myself at home?
A: Many patients or caregivers are taught to give Ziextenzo injections at home using prefilled syringes, but this should only be done after proper training and with clear instructions from the oncology team.

Q: What can I do about bone pain from Ziextenzo?
A: If you develop bone pain, talk with your clinician; they may recommend approved over-the-counter pain relievers or other strategies, and they will decide if any change in dosing is needed.

Q: Is Ziextenzo as effective and safe as Neulasta?
A: Ziextenzo is an FDA-approved biosimilar to Neulasta, meaning studies have shown it has no clinically meaningful differences in safety, purity, or effectiveness compared with the reference pegfilgrastim product when used at the same dose.

Storage
• Keep prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C); do not freeze; protect from light in the original carton.
• If needed, a single syringe may usually be kept at room temperature for a limited time (check the package instructions for the exact number of days) and then must not be returned to the refrigerator.
• Do not shake the syringe and do not use it if the solution is cloudy, discolored, or has particles.

Disposal
• Use Ziextenzo only once per syringe and throw away used syringes in an FDA-cleared sharps disposal container; do not recap needles or throw them into household trash or recycling.
• When the sharps container is about three-quarters full, follow local rules or product instructions for safe disposal (for example, community drop-off programs or mail-back programs).